This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2002; 101: 6–14.
Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O’Brien S, Wen S et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 26: 196–203.
Johnson BA, Geha M, Blackwell TK . Similar but distinct effects of the tristetraprolin/Tis11 immediate–early proteins on cell survival. Oncogene 2000; 19: 1657–1664.
Lee SK, Kim SB, Kim JS, Moon CH, Han MS, Lee BJ et al. Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines. Int J Cancer 2005; 117: 32–40.
Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J . The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent pathway. Blood 2002; 99: 1314–1319.
Brook M, Tchen CR, Santalucia T, McIlrath J, Arthur JS, Saklatvala J et al. Posttranslational regulation of tristetraprolin subcellular localisation and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol Cell Biol 2006; 26: 2408–2418.
Chrestensen CA, Schroeder MJ, Shabanowitz J, Hunt DF, Pelo JW, Worthington MT et al. MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. J Biol Chem 2004; 279: 10176–10184.
Cittera E, Onofri C, D’Apolito M, Cartron G, Cazzaniga G, Zelante L et al. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunol Immunother 2005; 54: 273–286.
Acknowledgements
We would like to thank Dr Perry Blackshear and Dr Seth Brook for providing us with the human cDNA for Tis11 used in northern blot analysis. We would also like to thank Dr David Flavell for providing Rituximab and Dr C Moroni for providing anti-Tis11b antibody.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Baou, M., Jewell, A., Muthurania, A. et al. Involvement of Tis11b, an AU-rich binding protein, in induction of apoptosis by rituximab in B cell chronic lymphocytic leukemia cells. Leukemia 23, 986–989 (2009). https://doi.org/10.1038/leu.2008.340
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.340
This article is cited by
-
The role of RNA-binding protein tristetraprolin in cancer and immunity
Medical Oncology (2017)
-
Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia
Nature Immunology (2010)